Dr. Richard D. Kim, MD

Dr. Kim practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Kim's NPI, 1609810779, was assigned on June 16, 2006. Dr. Kim graduated from University of Miami, Miller School of Medicine in 2000. Dr. Kim's Connecticut license number on file is 041492.

Dr. Kim's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Kim's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Kim to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kim practices, 2 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Kim's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Kim is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Kim's licenses on file in 3 states: Connecticut, Florida and Ohio.

Dmand AI lists colorectal cancer among the conditions Dr. Kim treats.

CMS data shows 301 Medicare services from Dr. Kim across 3 procedure codes in 2024, for 161 Medicare patients. Medicare paid $25,520 for them.

CMS counts 161 Medicare patients who saw Dr. Kim in 2024. The largest group is 65 to 74, with 98 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 2.45, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kim's median patient age at 69, with 46% women.

In 2024, Dr. Kim wrote 272 Medicare Part D claims for 98 patients. 76% of them were for generic drugs. CMS names the drug for 175 of them, across 7 drugs with 11 or more claims each, at $605,281 in total drug cost. In 2023, CMS named 147 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Kim for performance year 2024, reported as part of a group. Dr. Kim accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kim as offering telehealth.

Dmand AI links 174 papers to Dr. Kim, published from 2007 to 2025. 2020 was the busiest year, with 14. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms and Carcinoma, Hepatocellular. Dr. Kim has published most often in Oncologist. Dr. Kim's most frequent co-authors are Sarah Elizabeth Hoffe, MD, Daniel A. Anaya, MD and Jessica M. Frakes.

Dmand AI links Dr. Kim to 4 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Rectal Diseases, Esophageal Squamous Cell Carcinoma and Gallbladder Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 1,286 general payments to Dr. Kim from 49 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 48% of the total. Eli Lilly and Company paid the most, $206,652. It also lists 4 research payments totaling $3,396 from 2020 to 2025.

Dr. Kim graduated from University of Miami, Miller School of Medicine in 2000.

Dr. Kim is in network with 10 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.